HKSE - Delayed Quote HKD

InSilico Medicine Cayman TopCo (3696.HK)

37.260 +1.260 (+3.50%)

At close: 4:08:13 PM GMT+8

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Insilico Medicine Reports 40% ORR at 130 mg for Pan-TEAD Inhibitor ISM6331 Designed Using Generative AI in Heavily Pretreated Mesothelioma at ESMO 2026

PR Newswire 6d ago

3696.HK
+3.50%
Global Longevity BioTech Market Size and Forecast Report 2026-2030 | Capitalize on 10.7% CAGR as Insilico Medicine, Calico, and Altos Labs Lead the Industry

GlobeNewswire 12d ago

3696.HK
+3.50%
AI-driven Molecular Glue Innovation: Insilico Nominates ISM9546, an Oral, Peripheral-Restricted VAV1 Degrader as PCC for Autoimmune Diseases

PR Newswire 19d ago

3696.HK
+3.50%
Breaking the Safety Barrier: Insilico Medicine Nominates ISM1354, the Next-Generation Small Molecule GIPR Antagonist

PR Newswire 1mo ago

3696.HK
+3.50%
Capitalize on AI’s Drug Discovery Disruption: Benchmark NVIDIA, Schrödinger, Recursion, Insilico Medicine and Exscientia to Secure R&D ROI and Competitive Advantage Through 2030

GlobeNewswire 1mo ago

3696.HK
+3.50%
NVDA
Insilico Medicine (SEHK:3696) Takes Its AI Discovered Drug Into Phase III Trials

Simply Wall St. 1mo ago

3696.HK
+3.50%
Insilico Medicine’s Alex Zhavoronkov bets China and AI can deliver the drug industry’s next breakthrough

Fortune 1mo ago

3696.HK
+3.50%
Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drug

PR Newswire 1mo ago

3696.HK
+3.50%
Artificial Intelligence (AI) for De Novo Drug Design Global Market Report 2026 | Secure 33.7% CAGR Through 2030 with Schrödinger, XtalPi, Owkin, Insilico Medicine and Recursion

GlobeNewswire 5d ago

2228.HK

3696.HK
+3.50%
In-Silico Drug Discovery Market Report Now Available: Capitalize on AI-led R&D disruption as revenue surges from $3.3B to $6B by 2030; benchmark Certara, Insilico Medicine, Isomorphic Labs, Exscientia and BenevolentAI to secure share.

GlobeNewswire 1mo ago

CERT

3696.HK
+3.50%
Insilico Medicine Opens AI Longevity Discovery Toolkit to Researchers Worldwide in Cell Cover Study

PR Newswire 1mo ago

3696.HK
+3.50%
Nature Biotechnology | Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks

PR Newswire 1mo ago

3696.HK
+3.50%

Performance Overview

Return	3696.HK	HANG SENG INDEX (^HSI)
YTD	+0.70%	-8.59%
1-Year	+7.09%	-9.56%
3-Year	+7.09%	+35.98%

U.S. markets open in 5h 11m

InSilico Medicine Cayman TopCo (3696.HK)

Insilico Medicine Reports 40% ORR at 130 mg for Pan-TEAD Inhibitor ISM6331 Designed Using Generative AI in Heavily Pretreated Mesothelioma at ESMO 2026

Global Longevity BioTech Market Size and Forecast Report 2026-2030 | Capitalize on 10.7% CAGR as Insilico Medicine, Calico, and Altos Labs Lead the Industry

AI-driven Molecular Glue Innovation: Insilico Nominates ISM9546, an Oral, Peripheral-Restricted VAV1 Degrader as PCC for Autoimmune Diseases

Breaking the Safety Barrier: Insilico Medicine Nominates ISM1354, the Next-Generation Small Molecule GIPR Antagonist

Capitalize on AI’s Drug Discovery Disruption: Benchmark NVIDIA, Schrödinger, Recursion, Insilico Medicine and Exscientia to Secure R&D ROI and Competitive Advantage Through 2030

Insilico Medicine (SEHK:3696) Takes Its AI Discovered Drug Into Phase III Trials

Insilico Medicine’s Alex Zhavoronkov bets China and AI can deliver the drug industry’s next breakthrough

Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drug

Artificial Intelligence (AI) for De Novo Drug Design Global Market Report 2026 | Secure 33.7% CAGR Through 2030 with Schrödinger, XtalPi, Owkin, Insilico Medicine and Recursion

In-Silico Drug Discovery Market Report Now Available: Capitalize on AI-led R&D disruption as revenue surges from $3.3B to $6B by 2030; benchmark Certara, Insilico Medicine, Isomorphic Labs, Exscientia and BenevolentAI to secure share.

Insilico Medicine Opens AI Longevity Discovery Toolkit to Researchers Worldwide in Cell Cover Study

Nature Biotechnology | Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks